Seitz H K, Simanowski U A, Simon B, Kommerell B
Alcohol Research Laboratory, Department of Medicine, University of Heidelberg, F.R.G.
Z Gastroenterol. 1988 Mar;26(3):188-90.
Omeprazole, a substituted benzimidazole, is a potent gastric acid antisecretory drug, which inhibits the hepatic oxidative drug metabolism in vitro and in vivo. The effect of omeprazole on the microsomal ethanol oxidizing system (MEOS) and, since ethanol-induced cytochrome P-450 reveals a high activity for aniline hydroxylation, on aniline hydroxylase (AH) has been investigated in rat liver microsomes. Omeprazole inhibits microsomal AH activity significantly in a dose dependent manner, while this was not the case for MEOS activity. These data give indirect evidence that the microsomal metabolism of both ethanol and aniline is mediated by different isoenzymes of cytochrome P-450 and that omeprazole exhibits a different affinity to both compounds. Therefore, it must be emphasized that drug interactions with omeprazole have to be tested experimentally in each individual case, since it is impossible to predict such interactions solely on the knowledge of the drug's metabolic pathway.
奥美拉唑是一种取代苯并咪唑,是一种强效胃酸分泌抑制剂,在体外和体内均能抑制肝脏氧化药物代谢。在大鼠肝微粒体中研究了奥美拉唑对微粒体乙醇氧化系统(MEOS)的影响,由于乙醇诱导的细胞色素P-450对苯胺羟化具有高活性,因此也研究了其对苯胺羟化酶(AH)的影响。奥美拉唑以剂量依赖性方式显著抑制微粒体AH活性,而MEOS活性则不然。这些数据间接证明,乙醇和苯胺的微粒体代谢由细胞色素P-450的不同同工酶介导,且奥美拉唑对这两种化合物表现出不同的亲和力。因此,必须强调,与奥美拉唑的药物相互作用必须在每个具体案例中进行实验测试,因为仅根据药物的代谢途径知识无法预测此类相互作用。